Skip to main content
. Author manuscript; available in PMC: 2020 Oct 15.
Published in final edited form as: Am J Cardiol. 2019 Jul 24;124(8):1198–1206. doi: 10.1016/j.amjcard.2019.07.016

Figure 3.

Figure 3.

Comparison between event rate for composite ASCVD outcome and event rate for hospitalized major bleeding event (right axis) in MESA participants and comparison between predicted 5-year NNT to prevent 1 ischemic event and 5-year NNH to cause 1 bleeding event with rivaroxaban (left axis), stratified by (a) baseline CAC and (b) ASCVD risk prediction score by PCE. ASCVD = atherosclerotic cardiovascular disease; CAC = Coronary Artery Calcium; MESA = Multi-Ethnic Study in Atherosclerosis; NNH = number needed to harm; NNT = number needed to treat; PCE = Pooled Cohort Equations.